

Report from the Medical Oncology and Radiotherapy Subcommittee

Virtual SSG Working Group Meeting January 10 2022

Election of chairman for the medical oncology subcommittee

Kjetil Boye has been the chairman for six years, since the planned election last year was postponed due to the pandemic. Andri Papakonstantinou was the only candidate for the position and was unanimously elected.

First line treatment in advanced leiomyosarcoma: should we use dacarbazine?

Hans Hagberg presented the existing data on toxicity and efficacy on doxorubicin monotherapy, doxorubicin with ifosfamide and doxorubicin with dacarbazine in leiomyosarcoma. The presentation was followed by a discussion on our current practice. There are no conclusive, randomized evidence. The meeting nevertheless concluded that if combination therapy is chosen as first line treatment, doxorubicin and dacarbazine should be the preferred regimen.

The life after DOREMY: A register for preoperative radiotherapy in myxoid liposarcoma

Nina Jebesen presented the recently established international registry for preoperative radiotherapy in myxoid liposarcoma, which is led by Rick Haas in Amsterdam. Norway and Denmark are participating. It is not decided whether Sweden and Finland will join.

Adjuvant chemotherapy after preoperative radiotherapy in soft tissue sarcoma. How do we select high-risk patients?

Common session with orthopedic surgeons and pathologists. Kjetil Boye introduced the topic and outlined the challenges with risk classification after preoperative radiotherapy. The practice regarding adjuvant chemotherapy differs among centers, but the indication for adjuvant chemotherapy was not thoroughly discussed due to time. If used, the indication for adjuvant chemotherapy relies on the patient being classified with a high risk of distant metastasis after local treatment. Several risk classifications exist, and all include malignancy grade. The SSG has previously recommended the SSG XX criteria, which include vascular invasion, tumor size, tumor growth pattern and necrosis. After preoperative radiotherapy, malignancy grading, vascular invasion, tumor growth pattern and necrosis cannot reliably be evaluated. The challenges were discussed, but no consensus was reached. It was discussed that new studies to evaluate risk factors are needed, and there is an ongoing effort using data from the Swedish National Registry.

Study updates.

Kjetil Boye briefly mentioned the ongoing and planned studies in Ewing sarcoma (rEECur, iEuro-Ewing, Inter-Ewing-1) and rhabdomyosarcoma (FaR-RMS). The newly established European osteosarcoma consortium (FOSTER) was mentioned. There are currently no open studies in advanced STS across the Nordic countries. A study with propranolol and pembrolizumab in angiosarcoma and UPS led by Niels Junker is planned to open during 2022 in Copenhagen, Århus, Stockholm and Oslo. Nina Jebesen presented preliminary data on radiotherapy and local control from the SSG XX study. The main conclusion is that the toxicity is limited and local control is good.

Nina Jebsen and Kjetil Boye
January 11 2022